ILC2 orchestration of local immune function 1 in adipose tissue by Benezech, Cecile & Jackson-Jones, Lucy
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ILC2 orchestration of local immune function 1 in adipose tissue
Citation for published version:
Benezech, C & Jackson-Jones, L 2019, 'ILC2 orchestration of local immune function 1 in adipose tissue'
Frontiers in Immunology. DOI: 10.3389/fimmu.2019.00171
Digital Object Identifier (DOI):
10.3389/fimmu.2019.00171
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Frontiers in Immunology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
MINI REVIEW
published: 07 February 2019
doi: 10.3389/fimmu.2019.00171
Frontiers in Immunology | www.frontiersin.org 1 February 2019 | Volume 10 | Article 171
Edited by:
Jessica Borger,
Monash University, Australia
Reviewed by:
Timotheus You Fu Halim,
University of Cambridge,
United Kingdom
Massimo Vitale,
Azienda Ospedaliera Universitaria San
Martino (IRCCS), Italy
*Correspondence:
Cécile Bénézech
cbenezec@exseed.ed.ac.uk
Lucy Helen Jackson-Jones
l.jackson-jones@lancaster.ac.uk
Specialty section:
This article was submitted to
NK and Innate Lymphoid Cell Biology,
a section of the journal
Frontiers in Immunology
Received: 28 November 2018
Accepted: 21 January 2019
Published: 07 February 2019
Citation:
Bénézech C and Jackson-Jones LH
(2019) ILC2 Orchestration of Local
Immune Function in Adipose Tissue.
Front. Immunol. 10:171.
doi: 10.3389/fimmu.2019.00171
ILC2 Orchestration of Local Immune
Function in Adipose Tissue
Cécile Bénézech 1* and Lucy Helen Jackson-Jones 2*
1 BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, 2Division of Biomedical and
Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
ILC2s were originally identified as IL-5 and IL-13 secreting “natural helper cells” present
within the fat-associated lymphoid clusters of the mesenteries in both mouse and man.
The presence of ILCs in adipose tissue has more recently expanded to include all ILC
groups. Since their initial discovery, our knowledge of these cells and their role in adipose
immune responses has expanded significantly. In this review we summarize the current
literature on the role that ILC2s play in orchestrating adipose tissue function in both lean
and obese states. We go on to address new data detailing interactions of adipose ILCs
with innate like B-cells (IBC) and discuss how this interaction results in localized protection
of mucosal sites during infection and inflammation via the production of innate antibodies.
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INTRODUCTION
Innate lymphoid cells are the newest kids on the block in terms of innate immune cell function,
however the previous 8 years have revealed a wealth of information on these previously enigmatic
lymphocyte like cells. In a non-activated state, ILCs possess lymphocyte morphology but lack
the expression of surface markers used to define other immune cell populations. ILCs are
thus described as “lineage negative.” Non-cytotoxic ILCs are currently segregated into three
transcriptionally defined groups that mirror the four major T-helper cell subsets. Tbet dependent
ILC1s which secrete IFNγ and TNFα, GATA3 dependent ILC2s which secrete IL-5/IL-13 [and can
secrete IL-10 (1)], RORγt dependent ILC3s which secrete IL-17A/IL-22, and include a population of
Lymphoid tissue inducer (LTi) cells which are critical for secondary lymphoid organ development
(2) and finally, Id3 dependent ILCregs which produce IL-10 and require autocrine TGF-β1 (3). In
addition to these non-cytotoxic cell types, are the classical cytotoxic NK cells that are important
for protection against viruses and cancer. Although ILCs were first described as natural helper
cells (ILC2) in the fat-associated lymphoid clusters (FALCs) of the mesenteries where they support
antibody responses, their presence and importance has since been extended to the whole adipose
organ with ILCs having been reported inmost fat depots. ILCs are now considered as key regulators
of adipose tissue function. IBCs are B cells with “innate like” properties; they have a poly-specific
B-cell receptor repertoire and rapidly produce polyclonal IgM in response to both self andmicrobial
antigens (4). Here we will discuss (1) the central regulatory role of ILC2 in the regulation of adipose
tissue homeostasis and (2) the key role of ILCs in activation of the IBC compartment during
infection at mucosal sites.
ILC2s ARE CRITICAL REGULATORS OF TYPE 2 IMMUNE CELLS
TO MAINTAIN WHITE ADIPOSE TISSUE HOMEOSTASIS
Recently, it has become apparent that type 2 immune cells play a critical role in the maintenance
of homeostasis in lean, healthy adipose tissue and that ILC2 are central regulators of this function.
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Type 2 immune cells including ILC2, T regulatory cells (Treg),
T-helper type 2 cells (Th2), Eosinophils, mast cells, and M2
macrophages are prevalent in healthy adipose tissue where
they contribute to adipose tissue remodeling, counteracting the
inflammatory effect of obesity and inducing browning of white
adipose tissue (5, 6). Here, we will concentrate on the role of ILC2
in orchestrating the function of type 2 immune cells in adipose
tissue.
ILC2s and Immune Homeostasis in White
Adipose Tissue
ILC2s are present within visceral adipose tissue (VAT), where
they are the predominant producers of IL-5 and IL-13 at
homeostasis and following prolonged exposure to IL-33 or
helminth infection (7, 8). Th2 cells remain a minor population
of IL-5 and IL-13 producing cells within the VAT even during
helminth infection (8). In lean adipose tissue, IL-33 drives
the recruitment and/or proliferation of ILC2 but the cellular
origin of IL-33 and the mechanisms leading to its secretion
at homeostasis remains poorly understood. While we reported
that Gp38+ stromal cells of fat-associated lymphoid clusters
express high levels of IL-33, others showed that IL-33 is also
expressed by Gp38+ fibroblasts, Cadherin-11+ mesenchymal
cells, or endothelial cells of the stromal vascular fraction of
adipose tissue (9–12). It is likely that the relevant source of IL-
33 in adipose tissue is context dependent and further work is
needed to elucidate the mechanism of IL-33 action in adipose
tissue. Tissue ILC2s are key producers of systemic IL-5 required
for homeostatic eosinophil maintenance (13). In adipose tissue,
secretion of IL-5 by ILC2 is essential for the recruitment and
maintenance of eosinophils (8) and is dependent on IL-33 (8)
(Figure 1). Secretion of IL-13 and IL-4 by ILC2 and eosinophils is
critical for the maintenance of alternatively activated or M2-like
adipose tissue macrophages and glucose homeostasis (8, 14). The
precise phenotype and origin of these macrophages is not known.
Interestingly IL-33 has been shown to be competent to induce
macrophage proliferation independently of IL-4Rα expression in
other non-adipose macrophages populations (15) and whether
IL-33 can directly activate adipose tissue macrophages remains
to be investigated.
Pioneering work by the group of Diane Mathis demonstrated
the existence of a unique subset of GATA-3+ PPARγ+ regulatory
T cells in adipose tissue important for preventing insulin
resistance (16, 17). Regulatory T cells in adipose tissue express
the IL-33 receptor ST2 and require IL-33 for their maintenance
(18). Additionally, expression of ICOSL by adipose tissue ILC2
provides additional signaling through ICOS in regulatory T
cells for their accumulation within VAT (10). Halim et al.
elegantly advance these finding by showing that in the absence
of ILC2s or specifically the absence of OX40L expression by
ILC2s there is a significant deficit in the number of GATA3+ T-
regulatory cells within the perigonadal adipose tissue following
IL-33 delivery (19).
ILC2s and Adipose Tissue Browning
Brown and beige adipose tissue are fat depots specialized in
the dissipation of energy for the production of heat. While
brown adipose tissue is mostly found in infants and regresses
with age, white adipose tissue can undergo “browning” to form
beige adipose tissue, expressing the thermogenic protein Ucp1
during exposure to cold (20). Two distinct mechanisms involving
ILC2s have been implicated in the browning of adipose tissue.
Mechanism one relies on the IL-33 dependent induction of
methionine-enkephalin peptide release from ILC2s that acts
directly on adipocytes to upregulate UCP-1 and induce beiging
(21). The second published mechanism involves pharmacologic
expansion and activation of ILC2 with IL-33 in thermoneutral
mice which induces the proliferation of adipocytes and their
differentiation into beige adipocytes (22). This is dependent on
the release of IL-4 and IL-13 by ILC2 and the direct activation
of adipocyte precursor cells via the IL-4Rα (22). ILC2 may also
be important for the activation of eosinophils during acute cold
exposure and the secretion of IL-4/13, which have been reported
to induce browning through activation of alternatively activated
macrophage production of catecholamines (23). However, the
mechanisms leading to secretion of IL-33 upon cold exposure
were not elucidated. The production of catecholamines by
alternatively activated macrophages is controversial with a recent
report stating that alternatively activated macrophages do not
produce catecholamines and are thus unlikely to have a direct role
in adipocyte metabolism or adaptive thermogenesis (24).
Is There a Link Between the Gut Mucosa and the
Metabolic Regulatory Function of ILC2 in Adipose
Tissue?
In the small intestine, the release of IL-5 and IL-13 by ILC2
is increased by food intake, leading to fluctuation in the levels
of circulating eosinophils during the day (13). It would be
interesting to know if the secretion of IL-5 and IL-13 or other
important mediators such as methionine-enkephalin peptides by
adipose tissue ILC2s fluctuates with food intake, thus allowing
the synchronization of adipose tissue function with food intake
via immune regulation.
A LINK BETWEEN ADIPOSE TISSUE ILC2s
AND METABOLIC DYSFUNCTION
During obesity the number of ILC2s decreases in adipose tissue
both in mouse and human, leading to decrease in overall
Type-2 immunity and increased inflammation in adipose tissue.
Importantly, the loss of ILC2 in obesity can be reversed by
IL-33 injection in obese mice restoring glucose tolerance and
insulin sensitivity. However, the mechanisms leading to the loss
of ILC2 during obesity are not well-understood. Interestingly,
a population of ILC1s expand in the adipose tissue during
diet-induced obesity and produce IFN-γ in response to IL-12,
contributing to inflammation and insulin resistance (25). IFN-γ
has an antagonistic effect on ILC2 (10) which may be responsible
for the loss of ILC2 during obesity. It is also possible that IFNγ
and or IL-12 drives the conversion of ILC2 toward ILC1 during
diet-induced obesity, as described in response to IL-12 (26).
In addition, upregulation of PD-1 expression on ILC2 and its
engagement via PD-L1hi M1 macrophages has recently been
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FIGURE 1 | The ILC2 driven interactions that regulate immune adipose function. In the lean state (center; cream) IL-33 action (green arrows) signals to both
T-regulatory cells (Treg) and ILC2 resulting in regulated Type-2 immunity via the activity of secreted and membrane bound type-2 signals (blue arrows); this response is
amplified in the presence of lower ambient living temperature and during infancy and can result in browning thermogenesis within adipose tissue (Left; brown). Type-2
signals that can control browning are shown (brown arrows). In the obese state (right; pink) Inflammation mediated by type-1 signals (red arrows) promotes the
activation of ILC1 and the inhibition of ILC2 which results in inhibition of M2 and expansion of the M1 macrophage population which contribute to the development of
insulin resistance. During Type-2 inflammation within the lung or gut, ILC2 containing FALCs (Black circles) expand; IL-33 produced by stromal cells (green arrow)
increases IL-5 secretion (blue arrow) from ILC2 which induces innate like B cell (IBC) proliferation and secretion of IgM. (MetEnk, methionine-enkephalin peptides; NE,
norepinephrine; Eos, Eosinophils; IBC, Innate Like B cell; M1/M2, M1, or M2 macrophage; FALCs, Fat-associated lymphoid clusters).
described to inhibit the protective function of ILC2s during
obesity. Within obese adipose, increased PD-1 expression on
ILC2s was dependent on TNFα and IL-33 (27).
In the second half of this mini-review, the original role of
ILCs in the initiation of local immune function in FALCs is
discussed and extended to include the newly described pleural
FALCs (11, 28, 29); finally we discuss the interaction between
ILC2s, IBCs, and IgM during atherosclerosis.
FAT-ASSOCIATED LYMPHOID CLUSTER
FUNCTION IN MUCOSAL DEFENSE
The peritoneal and pleural cavities, primarily considered
as sites of macrophage (30) and B1 cell residence represent
compartments that demarcate, contain and protect the
boundaries between three major mucosal sites directly
exposed to environmental antigens; namely the lungs,
the intestines and the reproductive tract (of females)
(Figure 2). Immune protection within the body cavities is
co-ordinated by small, inducible lymphoid clusters found
within specialized small adipose tissues (the mediastinum,
pericardium, mesenteries, and omentum). Initially described
as “milky-spots” within the omentum (31) these inducible
structures were rebranded in 2010 as Fat-Associated Lymphoid
Clusters or FALCs (32). FALCs are local hubs that are
important for providing a second line of defense between
the mucosal surfaces and a systemic immune response,
working to compartmentalize antibody mediated immune
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FIGURE 2 | Compartmentalized protection of mucosal sites by fat-associated
lymphoid clusters within body cavities. Within the pleural cavity, protection
from/regulation of, microbiota, infection, inflammation, and damage is
mediated by inducible FALCs within the pericardium (green) and mediastinum
(orange). Within the peritoneal cavity, protection from/regulation of microbiota,
infection, inflammation, and damage is mediated by FALCs within the
omentum (purple) and mesenteries (pink) m, mediastinal; PeriC, pericardial;
om, omental; mes, mesenteric; FALCs, Fat-associated lymphoid clusters.
responses within body cavities. Evidence supporting FALC
orchestration of antibody responses within the body cavities
is mounting, with multiple reports linking FALCs to the
initiation of T-independent and T-dependent immune responses
(11, 29, 32–34).
FALCs, ILCs, AND THE INITIATION OF
INNATE LIKE B CELL RESPONSES
Intestinal Barrier Functions
FALCs were identified as immune cell aggregates within the
mesenteries, that were enriched in lineage negative, c-Kit+, Sca-
1+ cells; these cells are now known as ILC2s (32, 35, 36). ILC2s
are potent producers of IL-5 and IL-13; detectable levels of both
cytokines are induced in the peritoneal lavage of Rag2−/− mice
which do not have mature T or B cells, but are absent from
γ c−/−Rag2−/− following infection with the tissue migrating
parasite Nippostrongylus brasiliensis (32). This result highlighted
the potency of common-gamma chain receptor dependent innate
immune cells for the initiation of immune responses within the
peritoneal cavity in the context of intestinal worm infection. IL-5
is a critical growth factor for B1 B cells (37); Moro and colleagues
showed, using elegant in vivo transfers and in vitro co-cultures
of ILC2 with peritoneal B-cells in the presence or absence of
a blocking antibody against IL-5, that ILC2s provide support
for B1 cell self-renewal (32). ILC2s isolated from mesenteric
FALCs were also shown to be competent for the induction
of IgA secretion by peritoneal B cells in vitro (32). Peritoneal
B1 cells have been shown to migrate to the intestinal lamina
propria in order to secrete IgA (38, 39). In addition to the
conventional “Type-2” cytokines described above, ILC2 have
also been shown to secrete IL-6 (40, 41). As IL-6 has been
described to induce antibody production by B-cells, as well as
act as a growth factor for plasmablasts (42) and contribute to the
regulation of T follicular helper cells (43), it is plausible that ILC2
secretion of this cytokine locally modifies FALC B-cell function;
a hypothesis that warrants further experimental investigation
to confirm. Contrary to secondary organs, the development of
FALCs is not dependent on ILC3 as shown by the normal
development and composition of FALCs in Rorc−/− mice (29).
However, studies in germ free mice revealed that the number
of FALCs forming in the mesenteries is decreased indicating
that factors derived from the commensal flora are important to
drive the formation of FALCs. ILC3s are an important innate
source of GM-CSF, a cytokine required for the induction of IgM
by innate response activator (IRA) B cells (44). Competency to
support IgA secretion by B1 was also reported for peritoneal
macrophages, which had been exposed to omentum culture
supernatant (45). Given the almost certain presence of ILC
derived factors within the omental culture supernatant, it is
hard to know what component of the IgA secretion mediated
by peritoneal macrophages is in part dependent upon ILCs. A
thorough characterization of the ILC occupation of the murine
omentum has not been carried out; however a recent report
characterized the presence of ILCs in multiple human tissues
including detailing the presence of ILC1 like cells within the
omentum (46).
Pulmonary Barrier Functions
IgM is a large antibody and as such secretion of IgM into
the circulation does not guarantee its presence at tissue sites
where it is required. In the global absence of the IL-33R ST2,
the secretion of IgM from FALCs within the pleural cavity is
ablated (11). This is not a direct effect on the B-cells as co-
transfer of IL-33R sufficient and deficient B-cells resulted in
comparable induction of B-cell activation following Alternaria
alternata delivery. Utilizing blocking antibodies against IL-5
delivered directly into the pleural space, we concluded that the
IL-33 was acting via an IL-5 producing intermediate population
of cells. ILC2s were the only cells found to be expressing IL-5
within FALCs of the pleural cavity during type-2 inflammation
(11). Thus, the presence of IgM secreting B-cells within FALCs
in the context of type-2 inflammation is assumed to depend
upon IL-5 secretion from IL-33 activated ILC2s. The link between
ILC2 and antibody production within the thoracic cavity was
also made by Drake et al. (47) who showed that in vitro culture
of lung derived ILCs with splenic B cells resulted in antibody
production (47). However, as there are fewer B-cells within
the lungs and because fluid phase B cells isolated from the
pleural space do no secrete antibodies, it is likely that pleural
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FALCs are the sites where the ILC/B cell interactions take
place in the thoracic cavity. In support of a tight immune
crosstalk between lung and pleural space is a report showing that
delivery of GM-CSF secreting IRA B cells into the pleural space
mediates protection from pneumonia (48). Neither the role of
FALCs in the activation of the transferred IRA B cells nor the
requirement for lung or FALC resident ILCs in this process was
investigated. This study serves to further highlights the crosstalk
which occurs betweenmucosal tissues and their associated serous
cavities.
Is FALC Derived IgM Atheroprotective?
Innate like B-cells (IBCs) can be both protective and pathogenic
in atherosclerosis. Recognition of oxidation specific epitopes
on low density lipoproteins (LDL) (49) by natural IgM plays
a protective role in atherosclerosis and clinical studies show
that lower levels of IgM correlates with increased risk of
cardiovascular diseases. The production of atheroprotective IgM
by IBCs is dependent on IL-33 (50), IL-5 and IL-5 producing
ILC2 (51, 52), a signaling loop that is active in FALCs (11).
Importantly, it has been shown that the number of FALCs
in the para-aortic adipose of ApoE−/− mice increases in the
vicinity of atherosclerotic lesions (52) and that they contain
IBC producing atheroprotective IgM (53). This suggests that
ILC2 regulation of local IgM secretion by FALC IBCs could be
key to IBC mediated atheroprotection and that loss of ILC2
duringthe development of obesity could contribute to accelerated
atherosclerosis.
SUMMARY
Since their initial discovery 8 years ago, ILC2s have emerged
as major regulators of type-2 immunity in adipose tissue where
they co-ordinate eosinophil, macrophage, adipocyte and IBC
function. FALCs are specialized hubs that act as a second line of
immune defense sitting behind the mucosal frontline. Key to the
initiation of a FALC response is the local secretion of cytokines
by FALC resident ILCs, which kick-start the ensuing immune
response following detection of a danger signal (e.g., IL-33).
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